In a phase 1 trial of SAR3419, 39 patients with relapsed CD19+ B-cell lymphoma were treated with escalating doses of SAR3419 on an every 3 week schedule [51]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.